The use of VEGF as a predictive biomarker for bevacizumab therapy has remained inconclusive, however VEGF is a potent mediator of tumor angiogenesis and higher levels may be indicative of increased tumor angiogenesis and increased growth (19). This evidence concerns the gene VEGFA and neoplasm.